ImmuneRegen BioSciences, Inc. Founder, Director and Head Researcher, Dr. Mark Witten, Interviewed About Rapid Response Team and Stockpile Therapies in Event of Bioterrorism Attack

ImmuneRegen Executive discusses Rapid Response Team and Stockpile Therapies in Event of Bioterrorism Attack

Scottsdale, AZ (PRWEB) September 9, 2004 -- Dr. Mark Witten, Chief Scientist for ImmuneRegen BioSciences, Inc., (OTC BB: IRBO), was interviewed by CBS affiliate KOLD-TV and ABC affiliate KGUN-TV in Tucson, concerning the hovering threat of bioterrorism at the Republican National Convention as well as in and around the U.S. in the coming decade.

During the interviews, Dr. Witten indicated that the companys goal is to stockpile its proprietary compound Homspera" and have it ready to offer the government in an emergency situation to treat the detriments associated with a potential dirty bomb" or radioactive terrorism. Homspera can potentially reverse damage caused by exposure to acute radiation.

Anyone who would like a CD of aired interviews may make a request by email to mail@investorrelationsgroup.com

About ImmuneRegen BioSciences, Inc.
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc. (OTC BB: IRBO), is a biotechnology company engaged in the research and development of applications utilizing modified Substance P, a naturally occurring immunomodulator. Derived from homeostatic substance P, the company has named their proprietary compound "Homspera." The Company's initial focus is on the continuing development of Homspera for various applications for use in improving pulmonary function and stimulating the human immune system. For more information, please visit the company's website at www.immuneregen.com.

About Homspera
ImmuneRegen's patents and continued substance P research are derived from discoveries made during research funded by the Air Force Office of Scientific Research in the early 1990s. During this research, Dr. Witten and his associates observed that the exposure of animals to jet fuels resulted in pathological changes in the lung and immune systems of those exposed. It was also observed that such exposure resulted in depletion of substance P from the lungs of the animals. These studies further showed that the administration of substance P may help prevent and reverse the effects of jet fuel exposure in the lungs, as well as protect and regenerate the immune system. The immune findings led to early research on the treatment of exposure to acute radiation and on the possible reversal of lung damage caused by ARDS and cigarette smoke.

Statements about the Company's future expectations, including future revenues and earnings, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. The Company's actual results could differ materially from expected results as a result of a number of factors, including the uncertainties inherent in research collaborations, clinical trials and product development programs, the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Companys SEC filings.
###